-
PDF
- Split View
-
Views
-
Cite
Cite
Correction to: Trust in the attending rheumatologist, health-related hope and medication adherence among Japanese systemic lupus erythematosus patients, Rheumatology, Volume 62, Issue 8, August 2023, Pages 2938–2940, https://doi.org/10.1093/rheumatology/kead069
Close - Share Icon Share
This is a correction to: Noriaki Kurita, Nao Oguro, Yoshia Miyawaki, Chiharu Hidekawa, Natsuki Sakurai, Takanori Ichikawa, Yuichi Ishikawa, Keigo Hayashi, Kenta Shidahara, Dai Kishida, Ryusuke Yoshimi, Ken-ei Sada, Yasuhiro Shimojima, Nobuyuki Yajima, Trust in the attending rheumatologist, health-related hope and medication adherence among Japanese systemic lupus erythematosus patients, Rheumatology, 2022, https://doi.org/10.1093/rheumatology/keac565
In the originally published version of this manuscript, there were found minor scoring errors in the main exposure ‘health-related hope’ and in one covariate ‘basic health literacy’, and the data was reanalyzed. Tables needed to be corrected at the level of about one decimal place, but the conclusions of the paper are not affected apart from one sentence in Results section.
In Abstract, Results, the third sentence should read: “Both trust in one’s physician (per 10-point increase: 0.86, 95%CI 0.49, 1.22) and the Health-related Hope score (per 10-point increase: 0.66, 95% CI 0.35, 0.97) were associated with better medication adherence.” instead of: “Both trust in one’s physician (per 10-point increase: 0.88, 95% CI 0.53, 1.24) and the Health-related Hope score (per 10-point increase: 0.64, 95% CI 0.33, 0.95) were associated with better medication adherence.”.
In RESULTS, Patient characteristics section, the beginning of the fourth sentence should read: “The median basic health literacy score was 3.6 (IQR 3.2–4.0),” instead of: “The median basic health literacy score was 3.5 (IQR 3.0–4.0),”.
In RESULTS, figures were emended in the Trust in their rheumatologist, HR-Hope score, and correlates of the HR-Hope score section and should read: “The median score of trust in one’s physician was 80 (IQR 70−95), and the median HR-Hope score was 59.3 (IQR 44.4−68.6). Table 2 presents the association of the HR-Hope score with trust in one’s physician and patient characteristics. The HR-Hope score was positively associated with higher trust in one’s physician [per 10-point increase, 3.53 (95% CI 2.33, 4.74)] and basic health literacy [per 1-point increase, 5.85 (95% CI 2.38, 9.32)]. The HR-Hope score was inversely associated with being unmarried [vs married: −5.57 (95% CI −10.9, −0.97)], depression [−14.5 (95% CI −20.2, −8.80)], and concern regarding the number of medications [−6.07 (95% CI −11.4, −0.77)].” instead of: “The median score of trust in one’s physician was 80 (IQR 70−95), and the median HR-Hope score was 59.3 (IQR 44.4−70.4). Table 2 presents the association of the HR-Hope score with trust in one’s physician and patient characteristics. The HR-Hope score was positively associated with higher trust in one’s physician [per 10-point increase, 3.22 (95% CI 1.98, 4.45)] and basic health literacy [per 1-point increase, 5.86 (95% CI 2.70, 9.01)]. The HR-Hope score was inversely associated with being unmarried [vs married: −5.55 (95% CI −10.52 to −0.58)] and depression [−13.3 (95% CI −19.5 to −7.22)]. Evidence that the HR-Hope score was associated with concern regarding the number of medications [−5.97 (95% CI −12.1, 0.12)] was insufficient.”.
In RESULTS, figures were emended in the Association between the HR-Hope score, trust in one’s physician, and MAS score section and should read: “The MAS score increased with a higher HR-Hope score [per 10-point increase: 0.66 (95% CI 0.35, 0.97)] and higher trust in one’s physicians [per 10-point increase: 0.86 (95% CI 0.49, 1.22)].
Longer disease duration, especially those with >20 years, was also positively associated with a higher MAS score [vs <5 years: 2.01 (95% CI 0.18, 3.83)]. Experiencing lupus medication-related adverse effects and depression were also positively associated with the MAS score [2.18 (95% CI 0.85, 3.51) and 2.07 (95% CI 0.53, 3.62), respectively]. Concern regarding the number of lupus medications was inversely associated with the MAS score [−1.44 (95% CI −2.84, −0.049)].” instead of: “The MAS score increased with a higher HR-Hope score [per 10-point increase: 0.64 (95% CI 0.33, 0.95)] and higher trust in one’s physicians [per 10-point increase: 0.89 (95% CI 0.53, 1.24)].
Longer disease duration, especially those with >20 years, was also positively associated with a higher MAS score [vs <5 years: 1.9 (95% CI 0.09, 3.78)]. Experiencing lupus medication-related adverse effects and depression were also positively associated with the MAS score [2.28 (95% CI 0.98, 3.58) and 1.96 (95% CI 0.34, 3.59), respectively]. Concern regarding the number of lupus medications was inversely associated with the MAS score [−1.4 (95% CI −2.89, −0.004)].”.
In Table 1, details were corrected. These should read “Marital status, n(%)” instead of “Marital status”; “Basic health literacy, point 3.6 [3.2 − 4]” instead of: “Basic health literacy 3.5 [3 − 4]”.
In Table 2, figures on all lines were emended. The table should read:
Associations of hope with trust in their rheumatologists and patient characteristicsa (n = 373)
| . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|
| Trust in one’s physician, per 10-point increase | 3.53 (2.33, 4.74) | <0.001 |
| Basic health literacy, per 1-point increase | 5.85 (2.38, 9.32) | 0.001 |
| Age, per 10-year increase | −0.13 (−1.93, 1.68) | 0.891 |
| Female vs male subjects | −1.65 (−7.70, 4.41) | 0.593 |
| Marital status | ||
| Married | Reference | |
| Divorced/widowed | −3.24 (−12.1, 5.62) | 0.471 |
| Unmarried | −5.91 (−10.9 to −0.97) | 0.019 |
| Education | ||
| Junior high school or lower | Reference | |
| High school/college | −5.57 (−14.8, 3.65) | 0.234 |
| University/graduate school | −6.51 (−16.5, 3.43) | 0.198 |
| Household income | ||
| <1 000 000 yen (very low) | Reference | |
| 1 000 000 to <5 000 000 yen (low-medium) | 3.98 (−3.96, 11.9) | 0.322 |
| 5 000 000 to <10 000 000 yen (medium-high) | 7.37 (−0.74, 15.5) | 0.075 |
| >10 000 000 yen (high) | 7.65 (−3.41, 18.7) | 0.173 |
| Disease duration | ||
| <5 years | Reference | |
| 5 to <10 years | −1.11 (−7.63, 5.41) | 0.738 |
| 10 to <20 years | −0.71 (−6.77, 5.36) | 0.819 |
| >20 years | −0.29 (−7.02, 6.44) | 0.932 |
| SLEDAI-2K, per 1-point increase | 0.23 (−0.17, 0.64) | 0.260 |
| Depressive symptoms | −14.5 (−20.2, −8.80) | <0.001 |
| Experience of ADE within 1 month | 4.12 (−0.88, 9.13) | 0.106 |
| Concern for medication number | −6.07 (−11.4, 0.77) | 0.025 |
| Prednisolone dosage, per 1-mg increase | −0.12 (−0.40, 0.16) | 0.402 |
| Other immunosuppressants | 0.89 (−3.24, 5.02) | 0.671 |
| HCQ | 0.41 (−4.12, 4.94) | 0.859 |
| Prescription for dyslipidaemia | −0.92 (−5.55, 3.70) | 0.695 |
| Prescription for hypertension | 1.48 (−2.70, 5.66) | 0.486 |
| Prescription for diabetes | −2.68 (−11.2, 5.88) | 0.538 |
| Prescription for osteoporosis prevention | −0.27 (−5.17, 4.64) | 0.915 |
| Prescription for PCP prevention | −1.55 (−6.31, 3.21) | 0.522 |
| . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|
| Trust in one’s physician, per 10-point increase | 3.53 (2.33, 4.74) | <0.001 |
| Basic health literacy, per 1-point increase | 5.85 (2.38, 9.32) | 0.001 |
| Age, per 10-year increase | −0.13 (−1.93, 1.68) | 0.891 |
| Female vs male subjects | −1.65 (−7.70, 4.41) | 0.593 |
| Marital status | ||
| Married | Reference | |
| Divorced/widowed | −3.24 (−12.1, 5.62) | 0.471 |
| Unmarried | −5.91 (−10.9 to −0.97) | 0.019 |
| Education | ||
| Junior high school or lower | Reference | |
| High school/college | −5.57 (−14.8, 3.65) | 0.234 |
| University/graduate school | −6.51 (−16.5, 3.43) | 0.198 |
| Household income | ||
| <1 000 000 yen (very low) | Reference | |
| 1 000 000 to <5 000 000 yen (low-medium) | 3.98 (−3.96, 11.9) | 0.322 |
| 5 000 000 to <10 000 000 yen (medium-high) | 7.37 (−0.74, 15.5) | 0.075 |
| >10 000 000 yen (high) | 7.65 (−3.41, 18.7) | 0.173 |
| Disease duration | ||
| <5 years | Reference | |
| 5 to <10 years | −1.11 (−7.63, 5.41) | 0.738 |
| 10 to <20 years | −0.71 (−6.77, 5.36) | 0.819 |
| >20 years | −0.29 (−7.02, 6.44) | 0.932 |
| SLEDAI-2K, per 1-point increase | 0.23 (−0.17, 0.64) | 0.260 |
| Depressive symptoms | −14.5 (−20.2, −8.80) | <0.001 |
| Experience of ADE within 1 month | 4.12 (−0.88, 9.13) | 0.106 |
| Concern for medication number | −6.07 (−11.4, 0.77) | 0.025 |
| Prednisolone dosage, per 1-mg increase | −0.12 (−0.40, 0.16) | 0.402 |
| Other immunosuppressants | 0.89 (−3.24, 5.02) | 0.671 |
| HCQ | 0.41 (−4.12, 4.94) | 0.859 |
| Prescription for dyslipidaemia | −0.92 (−5.55, 3.70) | 0.695 |
| Prescription for hypertension | 1.48 (−2.70, 5.66) | 0.486 |
| Prescription for diabetes | −2.68 (−11.2, 5.88) | 0.538 |
| Prescription for osteoporosis prevention | −0.27 (−5.17, 4.64) | 0.915 |
| Prescription for PCP prevention | −1.55 (−6.31, 3.21) | 0.522 |
The general linear model was fit with inclusion of all variables listed above.
Bold font indicates significance at P < 0.05 in P-value column.
SLEDAI-2K: SLEDAI 2000; ADE: adverse drug event; PCP: Pneumocystis jirovecii pneumonia.
Associations of hope with trust in their rheumatologists and patient characteristicsa (n = 373)
| . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|
| Trust in one’s physician, per 10-point increase | 3.53 (2.33, 4.74) | <0.001 |
| Basic health literacy, per 1-point increase | 5.85 (2.38, 9.32) | 0.001 |
| Age, per 10-year increase | −0.13 (−1.93, 1.68) | 0.891 |
| Female vs male subjects | −1.65 (−7.70, 4.41) | 0.593 |
| Marital status | ||
| Married | Reference | |
| Divorced/widowed | −3.24 (−12.1, 5.62) | 0.471 |
| Unmarried | −5.91 (−10.9 to −0.97) | 0.019 |
| Education | ||
| Junior high school or lower | Reference | |
| High school/college | −5.57 (−14.8, 3.65) | 0.234 |
| University/graduate school | −6.51 (−16.5, 3.43) | 0.198 |
| Household income | ||
| <1 000 000 yen (very low) | Reference | |
| 1 000 000 to <5 000 000 yen (low-medium) | 3.98 (−3.96, 11.9) | 0.322 |
| 5 000 000 to <10 000 000 yen (medium-high) | 7.37 (−0.74, 15.5) | 0.075 |
| >10 000 000 yen (high) | 7.65 (−3.41, 18.7) | 0.173 |
| Disease duration | ||
| <5 years | Reference | |
| 5 to <10 years | −1.11 (−7.63, 5.41) | 0.738 |
| 10 to <20 years | −0.71 (−6.77, 5.36) | 0.819 |
| >20 years | −0.29 (−7.02, 6.44) | 0.932 |
| SLEDAI-2K, per 1-point increase | 0.23 (−0.17, 0.64) | 0.260 |
| Depressive symptoms | −14.5 (−20.2, −8.80) | <0.001 |
| Experience of ADE within 1 month | 4.12 (−0.88, 9.13) | 0.106 |
| Concern for medication number | −6.07 (−11.4, 0.77) | 0.025 |
| Prednisolone dosage, per 1-mg increase | −0.12 (−0.40, 0.16) | 0.402 |
| Other immunosuppressants | 0.89 (−3.24, 5.02) | 0.671 |
| HCQ | 0.41 (−4.12, 4.94) | 0.859 |
| Prescription for dyslipidaemia | −0.92 (−5.55, 3.70) | 0.695 |
| Prescription for hypertension | 1.48 (−2.70, 5.66) | 0.486 |
| Prescription for diabetes | −2.68 (−11.2, 5.88) | 0.538 |
| Prescription for osteoporosis prevention | −0.27 (−5.17, 4.64) | 0.915 |
| Prescription for PCP prevention | −1.55 (−6.31, 3.21) | 0.522 |
| . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|
| Trust in one’s physician, per 10-point increase | 3.53 (2.33, 4.74) | <0.001 |
| Basic health literacy, per 1-point increase | 5.85 (2.38, 9.32) | 0.001 |
| Age, per 10-year increase | −0.13 (−1.93, 1.68) | 0.891 |
| Female vs male subjects | −1.65 (−7.70, 4.41) | 0.593 |
| Marital status | ||
| Married | Reference | |
| Divorced/widowed | −3.24 (−12.1, 5.62) | 0.471 |
| Unmarried | −5.91 (−10.9 to −0.97) | 0.019 |
| Education | ||
| Junior high school or lower | Reference | |
| High school/college | −5.57 (−14.8, 3.65) | 0.234 |
| University/graduate school | −6.51 (−16.5, 3.43) | 0.198 |
| Household income | ||
| <1 000 000 yen (very low) | Reference | |
| 1 000 000 to <5 000 000 yen (low-medium) | 3.98 (−3.96, 11.9) | 0.322 |
| 5 000 000 to <10 000 000 yen (medium-high) | 7.37 (−0.74, 15.5) | 0.075 |
| >10 000 000 yen (high) | 7.65 (−3.41, 18.7) | 0.173 |
| Disease duration | ||
| <5 years | Reference | |
| 5 to <10 years | −1.11 (−7.63, 5.41) | 0.738 |
| 10 to <20 years | −0.71 (−6.77, 5.36) | 0.819 |
| >20 years | −0.29 (−7.02, 6.44) | 0.932 |
| SLEDAI-2K, per 1-point increase | 0.23 (−0.17, 0.64) | 0.260 |
| Depressive symptoms | −14.5 (−20.2, −8.80) | <0.001 |
| Experience of ADE within 1 month | 4.12 (−0.88, 9.13) | 0.106 |
| Concern for medication number | −6.07 (−11.4, 0.77) | 0.025 |
| Prednisolone dosage, per 1-mg increase | −0.12 (−0.40, 0.16) | 0.402 |
| Other immunosuppressants | 0.89 (−3.24, 5.02) | 0.671 |
| HCQ | 0.41 (−4.12, 4.94) | 0.859 |
| Prescription for dyslipidaemia | −0.92 (−5.55, 3.70) | 0.695 |
| Prescription for hypertension | 1.48 (−2.70, 5.66) | 0.486 |
| Prescription for diabetes | −2.68 (−11.2, 5.88) | 0.538 |
| Prescription for osteoporosis prevention | −0.27 (−5.17, 4.64) | 0.915 |
| Prescription for PCP prevention | −1.55 (−6.31, 3.21) | 0.522 |
The general linear model was fit with inclusion of all variables listed above.
Bold font indicates significance at P < 0.05 in P-value column.
SLEDAI-2K: SLEDAI 2000; ADE: adverse drug event; PCP: Pneumocystis jirovecii pneumonia.
instead of:
Associations of hope with trust in their rheumatologists and patient characteristicsa (n = 373)
| . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|
| Trust in one’s physician, per 10-point increase | 3.22 (1.98, 4.45) | <0.001 |
| Basic health literacy, per 1-point increase | 5.86 (2.7, 9.01) | <0.001 |
| Age, per 10-year increase | 0.01 (−1.81, 1.84) | 0.987 |
| Female vs male subjects | −0.55 (−7.52, 6.41) | 0.876 |
| Marital status | ||
| Married | Reference | |
| Divorced/widowed | −3.38 (−12.7, 5.97) | 0.475 |
| Unmarried | −5.55 (−10.5 to −0.58) | 0.029 |
| Education | ||
| Junior high school or lower | Reference | |
| High school/college | −3.33 (−13.5, 6.8) | 0.515 |
| University/graduate school | −3.84 (−15.1, 7.38) | 0.498 |
| Household income | ||
| <1 000 000 yen (very low) | Reference | |
| 1 000 000 to <5 000 000 yen (low-medium) | 4.08 (−4.7, 12.9) | 0.357 |
| 5 000 000 to <10 000 000 yen (medium-high) | 8.41 (−0.93, 17.8) | 0.077 |
| >10 000 000 yen (high) | 7.68 (−3.36, 18.7) | 0.171 |
| Disease duration | ||
| <5 years | Reference | |
| 5 to <10 years | −1.22 (−7.8, 5.37) | 0.716 |
| 10 to <20 years | −0.87 (−6.88, 5.13) | 0.775 |
| >20 years | −0.76 (−7.54, 6.01) | 0.825 |
| SLEDAI-2K, per 1-point increase | 0.22 (−0.22, 0.66) | 0.325 |
| Depressive symptoms | −13.3 (−19.5, −7.22) | <0.001 |
| Experience of ADE within 1 month | 4.49 (−0.91, 9.89) | 0.102 |
| Concern for medication number | −5.97 (−12.1, 0.12) | 0.054 |
| Prednisolone dosage, per 1-mg increase | −0.14 (−0.44, 0.17) | 0.387 |
| Other immunosuppressants | 1.32 (−3.03, 5.67) | 0.550 |
| HCQ | 0.41 (−4.21, 5.02) | 0.863 |
| Prescription for dyslipidaemia | −1.81 (−6.9, 3.29) | 0.485 |
| Prescription for hypertension | 1.18 (−3.25, 5.62) | 0.599 |
| Prescription for diabetes | −2.16 (−11.3, 7.01) | 0.642 |
| Prescription for osteoporosis prevention | −0.62 (−5.8, 4.57) | 0.815 |
| Prescription for PCP prevention | −0.58 (−5.41, 4.26) | 0.815 |
| . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|
| Trust in one’s physician, per 10-point increase | 3.22 (1.98, 4.45) | <0.001 |
| Basic health literacy, per 1-point increase | 5.86 (2.7, 9.01) | <0.001 |
| Age, per 10-year increase | 0.01 (−1.81, 1.84) | 0.987 |
| Female vs male subjects | −0.55 (−7.52, 6.41) | 0.876 |
| Marital status | ||
| Married | Reference | |
| Divorced/widowed | −3.38 (−12.7, 5.97) | 0.475 |
| Unmarried | −5.55 (−10.5 to −0.58) | 0.029 |
| Education | ||
| Junior high school or lower | Reference | |
| High school/college | −3.33 (−13.5, 6.8) | 0.515 |
| University/graduate school | −3.84 (−15.1, 7.38) | 0.498 |
| Household income | ||
| <1 000 000 yen (very low) | Reference | |
| 1 000 000 to <5 000 000 yen (low-medium) | 4.08 (−4.7, 12.9) | 0.357 |
| 5 000 000 to <10 000 000 yen (medium-high) | 8.41 (−0.93, 17.8) | 0.077 |
| >10 000 000 yen (high) | 7.68 (−3.36, 18.7) | 0.171 |
| Disease duration | ||
| <5 years | Reference | |
| 5 to <10 years | −1.22 (−7.8, 5.37) | 0.716 |
| 10 to <20 years | −0.87 (−6.88, 5.13) | 0.775 |
| >20 years | −0.76 (−7.54, 6.01) | 0.825 |
| SLEDAI-2K, per 1-point increase | 0.22 (−0.22, 0.66) | 0.325 |
| Depressive symptoms | −13.3 (−19.5, −7.22) | <0.001 |
| Experience of ADE within 1 month | 4.49 (−0.91, 9.89) | 0.102 |
| Concern for medication number | −5.97 (−12.1, 0.12) | 0.054 |
| Prednisolone dosage, per 1-mg increase | −0.14 (−0.44, 0.17) | 0.387 |
| Other immunosuppressants | 1.32 (−3.03, 5.67) | 0.550 |
| HCQ | 0.41 (−4.21, 5.02) | 0.863 |
| Prescription for dyslipidaemia | −1.81 (−6.9, 3.29) | 0.485 |
| Prescription for hypertension | 1.18 (−3.25, 5.62) | 0.599 |
| Prescription for diabetes | −2.16 (−11.3, 7.01) | 0.642 |
| Prescription for osteoporosis prevention | −0.62 (−5.8, 4.57) | 0.815 |
| Prescription for PCP prevention | −0.58 (−5.41, 4.26) | 0.815 |
The general linear model was fit with inclusion of all variables listed above.
Bold font indicates significance at P < 0.05 in P-value column.
SLEDAI-2K: SLEDAI 2000; ADE: adverse drug event; PCP: Pneumocystis jirovecii pneumonia.
Associations of hope with trust in their rheumatologists and patient characteristicsa (n = 373)
| . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|
| Trust in one’s physician, per 10-point increase | 3.22 (1.98, 4.45) | <0.001 |
| Basic health literacy, per 1-point increase | 5.86 (2.7, 9.01) | <0.001 |
| Age, per 10-year increase | 0.01 (−1.81, 1.84) | 0.987 |
| Female vs male subjects | −0.55 (−7.52, 6.41) | 0.876 |
| Marital status | ||
| Married | Reference | |
| Divorced/widowed | −3.38 (−12.7, 5.97) | 0.475 |
| Unmarried | −5.55 (−10.5 to −0.58) | 0.029 |
| Education | ||
| Junior high school or lower | Reference | |
| High school/college | −3.33 (−13.5, 6.8) | 0.515 |
| University/graduate school | −3.84 (−15.1, 7.38) | 0.498 |
| Household income | ||
| <1 000 000 yen (very low) | Reference | |
| 1 000 000 to <5 000 000 yen (low-medium) | 4.08 (−4.7, 12.9) | 0.357 |
| 5 000 000 to <10 000 000 yen (medium-high) | 8.41 (−0.93, 17.8) | 0.077 |
| >10 000 000 yen (high) | 7.68 (−3.36, 18.7) | 0.171 |
| Disease duration | ||
| <5 years | Reference | |
| 5 to <10 years | −1.22 (−7.8, 5.37) | 0.716 |
| 10 to <20 years | −0.87 (−6.88, 5.13) | 0.775 |
| >20 years | −0.76 (−7.54, 6.01) | 0.825 |
| SLEDAI-2K, per 1-point increase | 0.22 (−0.22, 0.66) | 0.325 |
| Depressive symptoms | −13.3 (−19.5, −7.22) | <0.001 |
| Experience of ADE within 1 month | 4.49 (−0.91, 9.89) | 0.102 |
| Concern for medication number | −5.97 (−12.1, 0.12) | 0.054 |
| Prednisolone dosage, per 1-mg increase | −0.14 (−0.44, 0.17) | 0.387 |
| Other immunosuppressants | 1.32 (−3.03, 5.67) | 0.550 |
| HCQ | 0.41 (−4.21, 5.02) | 0.863 |
| Prescription for dyslipidaemia | −1.81 (−6.9, 3.29) | 0.485 |
| Prescription for hypertension | 1.18 (−3.25, 5.62) | 0.599 |
| Prescription for diabetes | −2.16 (−11.3, 7.01) | 0.642 |
| Prescription for osteoporosis prevention | −0.62 (−5.8, 4.57) | 0.815 |
| Prescription for PCP prevention | −0.58 (−5.41, 4.26) | 0.815 |
| . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|
| Trust in one’s physician, per 10-point increase | 3.22 (1.98, 4.45) | <0.001 |
| Basic health literacy, per 1-point increase | 5.86 (2.7, 9.01) | <0.001 |
| Age, per 10-year increase | 0.01 (−1.81, 1.84) | 0.987 |
| Female vs male subjects | −0.55 (−7.52, 6.41) | 0.876 |
| Marital status | ||
| Married | Reference | |
| Divorced/widowed | −3.38 (−12.7, 5.97) | 0.475 |
| Unmarried | −5.55 (−10.5 to −0.58) | 0.029 |
| Education | ||
| Junior high school or lower | Reference | |
| High school/college | −3.33 (−13.5, 6.8) | 0.515 |
| University/graduate school | −3.84 (−15.1, 7.38) | 0.498 |
| Household income | ||
| <1 000 000 yen (very low) | Reference | |
| 1 000 000 to <5 000 000 yen (low-medium) | 4.08 (−4.7, 12.9) | 0.357 |
| 5 000 000 to <10 000 000 yen (medium-high) | 8.41 (−0.93, 17.8) | 0.077 |
| >10 000 000 yen (high) | 7.68 (−3.36, 18.7) | 0.171 |
| Disease duration | ||
| <5 years | Reference | |
| 5 to <10 years | −1.22 (−7.8, 5.37) | 0.716 |
| 10 to <20 years | −0.87 (−6.88, 5.13) | 0.775 |
| >20 years | −0.76 (−7.54, 6.01) | 0.825 |
| SLEDAI-2K, per 1-point increase | 0.22 (−0.22, 0.66) | 0.325 |
| Depressive symptoms | −13.3 (−19.5, −7.22) | <0.001 |
| Experience of ADE within 1 month | 4.49 (−0.91, 9.89) | 0.102 |
| Concern for medication number | −5.97 (−12.1, 0.12) | 0.054 |
| Prednisolone dosage, per 1-mg increase | −0.14 (−0.44, 0.17) | 0.387 |
| Other immunosuppressants | 1.32 (−3.03, 5.67) | 0.550 |
| HCQ | 0.41 (−4.21, 5.02) | 0.863 |
| Prescription for dyslipidaemia | −1.81 (−6.9, 3.29) | 0.485 |
| Prescription for hypertension | 1.18 (−3.25, 5.62) | 0.599 |
| Prescription for diabetes | −2.16 (−11.3, 7.01) | 0.642 |
| Prescription for osteoporosis prevention | −0.62 (−5.8, 4.57) | 0.815 |
| Prescription for PCP prevention | −0.58 (−5.41, 4.26) | 0.815 |
The general linear model was fit with inclusion of all variables listed above.
Bold font indicates significance at P < 0.05 in P-value column.
SLEDAI-2K: SLEDAI 2000; ADE: adverse drug event; PCP: Pneumocystis jirovecii pneumonia.
In Table 3, figures on all lines were emended. The table should read:
Associations of medication adherence with the Health-related Hope score, trust in the physician, and covariatesa (n = 373)
| . | Corresponding standardized ES . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|---|
| Health-related Hope, per 10-point increase | 0.13 | 0.66 (0.35, 0.97) | <0.001 |
| Trust in one’s physician, per 10-point increase | 0.16 | 0.86 (0.49, 1.22) | <0.001 |
| Basic health literacy, per 1-point increase | −0.06 | −0.32 (−1.27, 0.63) | 0.511 |
| Age, per 10-year increase | −0.02 | −0.12 (−0.62, 0.37) | 0.624 |
| Female vs male subjects | 0.31 | 1.61 (−0.09, 3.30) | 0.063 |
| Marital status | |||
| Married | Reference | ||
| Divorced/widowed | −0.02 | −0.13 (−2.43, 2.18) | 0.914 |
| Unmarried | 0.21 | 1.12 (−0.21, 2.46) | 0.098 |
| Education | |||
| Junior high school or lower | Reference | ||
| High school/college | 0.05 | 0.26 (−2.28, 2.81) | 0.839 |
| University/graduate school | 0.12 | 0.61 (−2.21, 3.43) | 0.669 |
| Household income | |||
| <1 000 000 yen (very low) | Reference | ||
| 1 000 000–<5 000 000 yen (low-medium) | 0.11 | 0.59 (−1.41, 2.59) | 0.562 |
| 5 000 000–<10 000 000 yen (medium-high) | 0.20 | 1.06 (−1.02, 3.14) | 0.317 |
| >10 000 000 yen (high) | 0.19 | 1.00 (−1.93, 3.92) | 0.502 |
| Disease duration | |||
| <5 years | Reference | ||
| 5 to <10 years | 0.21 | 1.11 (−0.69, 2.90) | 0.225 |
| 10 to <20 years | 0.19 | 1.02 (−0.63, 2.67) | 0.226 |
| >20 years | 0.38 | 2.01 (0.18, 3.83) | 0.031 |
| SLEDAI-2K, per 1-point increase | 0 | −0.01 (−0.12, 0.11) | 0.924 |
| Depressive symptom | 0.39 | 2.07 (0.53, 3.62) | 0.009 |
| Experience of ADE within 1 month | 0.42 | 2.18 (0.85, 3.51) | 0.001 |
| Concern for medication number | −0.28 | −1.44 (−2.84, −0.049) | 0.043 |
| Prednisolone dosage, per 1-mg increase | 0 | 0.01 (−0.08, 0.09) | 0.900 |
| Other immunosuppressants | −0.13 | −0.66 (−1.80, 0.48) | 0.258 |
| HCQ | 0.04 | 0.22 (−1.01, 1.45) | 0.723 |
| Prescription for dyslipidaemia | −0.02 | −0.12 (−1.39, 1.14) | 0.850 |
| Prescription for hypertension | −0.05 | −0.27 (−1.40, 0.86) | 0.640 |
| Prescription for diabetes | 0.06 | 0.31 (−1.98, 2.61) | 0.787 |
| Prescription for osteoporosis prevention | 0.20 | 1.07 (−0.27, 2.41) | 0.116 |
| Prescription for PCP prevention | −0.05 | −0.28 (−1.58, 1.01) | 0.669 |
| . | Corresponding standardized ES . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|---|
| Health-related Hope, per 10-point increase | 0.13 | 0.66 (0.35, 0.97) | <0.001 |
| Trust in one’s physician, per 10-point increase | 0.16 | 0.86 (0.49, 1.22) | <0.001 |
| Basic health literacy, per 1-point increase | −0.06 | −0.32 (−1.27, 0.63) | 0.511 |
| Age, per 10-year increase | −0.02 | −0.12 (−0.62, 0.37) | 0.624 |
| Female vs male subjects | 0.31 | 1.61 (−0.09, 3.30) | 0.063 |
| Marital status | |||
| Married | Reference | ||
| Divorced/widowed | −0.02 | −0.13 (−2.43, 2.18) | 0.914 |
| Unmarried | 0.21 | 1.12 (−0.21, 2.46) | 0.098 |
| Education | |||
| Junior high school or lower | Reference | ||
| High school/college | 0.05 | 0.26 (−2.28, 2.81) | 0.839 |
| University/graduate school | 0.12 | 0.61 (−2.21, 3.43) | 0.669 |
| Household income | |||
| <1 000 000 yen (very low) | Reference | ||
| 1 000 000–<5 000 000 yen (low-medium) | 0.11 | 0.59 (−1.41, 2.59) | 0.562 |
| 5 000 000–<10 000 000 yen (medium-high) | 0.20 | 1.06 (−1.02, 3.14) | 0.317 |
| >10 000 000 yen (high) | 0.19 | 1.00 (−1.93, 3.92) | 0.502 |
| Disease duration | |||
| <5 years | Reference | ||
| 5 to <10 years | 0.21 | 1.11 (−0.69, 2.90) | 0.225 |
| 10 to <20 years | 0.19 | 1.02 (−0.63, 2.67) | 0.226 |
| >20 years | 0.38 | 2.01 (0.18, 3.83) | 0.031 |
| SLEDAI-2K, per 1-point increase | 0 | −0.01 (−0.12, 0.11) | 0.924 |
| Depressive symptom | 0.39 | 2.07 (0.53, 3.62) | 0.009 |
| Experience of ADE within 1 month | 0.42 | 2.18 (0.85, 3.51) | 0.001 |
| Concern for medication number | −0.28 | −1.44 (−2.84, −0.049) | 0.043 |
| Prednisolone dosage, per 1-mg increase | 0 | 0.01 (−0.08, 0.09) | 0.900 |
| Other immunosuppressants | −0.13 | −0.66 (−1.80, 0.48) | 0.258 |
| HCQ | 0.04 | 0.22 (−1.01, 1.45) | 0.723 |
| Prescription for dyslipidaemia | −0.02 | −0.12 (−1.39, 1.14) | 0.850 |
| Prescription for hypertension | −0.05 | −0.27 (−1.40, 0.86) | 0.640 |
| Prescription for diabetes | 0.06 | 0.31 (−1.98, 2.61) | 0.787 |
| Prescription for osteoporosis prevention | 0.20 | 1.07 (−0.27, 2.41) | 0.116 |
| Prescription for PCP prevention | −0.05 | −0.28 (−1.58, 1.01) | 0.669 |
The general linear model was fit with inclusion of all variables listed above. To calculate the corresponding standardized ES (Cohen’s d), the point estimate was divided by the s.d. of the medication adherence scale score.
Bold font indicates significance at P < 0.05 in P-value column. ES: effect size; SLEDAI-2K: SLEDAI 2000; ADE: adverse drug event; PCP: Pneumocystis jirovecii pneumonia.
Associations of medication adherence with the Health-related Hope score, trust in the physician, and covariatesa (n = 373)
| . | Corresponding standardized ES . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|---|
| Health-related Hope, per 10-point increase | 0.13 | 0.66 (0.35, 0.97) | <0.001 |
| Trust in one’s physician, per 10-point increase | 0.16 | 0.86 (0.49, 1.22) | <0.001 |
| Basic health literacy, per 1-point increase | −0.06 | −0.32 (−1.27, 0.63) | 0.511 |
| Age, per 10-year increase | −0.02 | −0.12 (−0.62, 0.37) | 0.624 |
| Female vs male subjects | 0.31 | 1.61 (−0.09, 3.30) | 0.063 |
| Marital status | |||
| Married | Reference | ||
| Divorced/widowed | −0.02 | −0.13 (−2.43, 2.18) | 0.914 |
| Unmarried | 0.21 | 1.12 (−0.21, 2.46) | 0.098 |
| Education | |||
| Junior high school or lower | Reference | ||
| High school/college | 0.05 | 0.26 (−2.28, 2.81) | 0.839 |
| University/graduate school | 0.12 | 0.61 (−2.21, 3.43) | 0.669 |
| Household income | |||
| <1 000 000 yen (very low) | Reference | ||
| 1 000 000–<5 000 000 yen (low-medium) | 0.11 | 0.59 (−1.41, 2.59) | 0.562 |
| 5 000 000–<10 000 000 yen (medium-high) | 0.20 | 1.06 (−1.02, 3.14) | 0.317 |
| >10 000 000 yen (high) | 0.19 | 1.00 (−1.93, 3.92) | 0.502 |
| Disease duration | |||
| <5 years | Reference | ||
| 5 to <10 years | 0.21 | 1.11 (−0.69, 2.90) | 0.225 |
| 10 to <20 years | 0.19 | 1.02 (−0.63, 2.67) | 0.226 |
| >20 years | 0.38 | 2.01 (0.18, 3.83) | 0.031 |
| SLEDAI-2K, per 1-point increase | 0 | −0.01 (−0.12, 0.11) | 0.924 |
| Depressive symptom | 0.39 | 2.07 (0.53, 3.62) | 0.009 |
| Experience of ADE within 1 month | 0.42 | 2.18 (0.85, 3.51) | 0.001 |
| Concern for medication number | −0.28 | −1.44 (−2.84, −0.049) | 0.043 |
| Prednisolone dosage, per 1-mg increase | 0 | 0.01 (−0.08, 0.09) | 0.900 |
| Other immunosuppressants | −0.13 | −0.66 (−1.80, 0.48) | 0.258 |
| HCQ | 0.04 | 0.22 (−1.01, 1.45) | 0.723 |
| Prescription for dyslipidaemia | −0.02 | −0.12 (−1.39, 1.14) | 0.850 |
| Prescription for hypertension | −0.05 | −0.27 (−1.40, 0.86) | 0.640 |
| Prescription for diabetes | 0.06 | 0.31 (−1.98, 2.61) | 0.787 |
| Prescription for osteoporosis prevention | 0.20 | 1.07 (−0.27, 2.41) | 0.116 |
| Prescription for PCP prevention | −0.05 | −0.28 (−1.58, 1.01) | 0.669 |
| . | Corresponding standardized ES . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|---|
| Health-related Hope, per 10-point increase | 0.13 | 0.66 (0.35, 0.97) | <0.001 |
| Trust in one’s physician, per 10-point increase | 0.16 | 0.86 (0.49, 1.22) | <0.001 |
| Basic health literacy, per 1-point increase | −0.06 | −0.32 (−1.27, 0.63) | 0.511 |
| Age, per 10-year increase | −0.02 | −0.12 (−0.62, 0.37) | 0.624 |
| Female vs male subjects | 0.31 | 1.61 (−0.09, 3.30) | 0.063 |
| Marital status | |||
| Married | Reference | ||
| Divorced/widowed | −0.02 | −0.13 (−2.43, 2.18) | 0.914 |
| Unmarried | 0.21 | 1.12 (−0.21, 2.46) | 0.098 |
| Education | |||
| Junior high school or lower | Reference | ||
| High school/college | 0.05 | 0.26 (−2.28, 2.81) | 0.839 |
| University/graduate school | 0.12 | 0.61 (−2.21, 3.43) | 0.669 |
| Household income | |||
| <1 000 000 yen (very low) | Reference | ||
| 1 000 000–<5 000 000 yen (low-medium) | 0.11 | 0.59 (−1.41, 2.59) | 0.562 |
| 5 000 000–<10 000 000 yen (medium-high) | 0.20 | 1.06 (−1.02, 3.14) | 0.317 |
| >10 000 000 yen (high) | 0.19 | 1.00 (−1.93, 3.92) | 0.502 |
| Disease duration | |||
| <5 years | Reference | ||
| 5 to <10 years | 0.21 | 1.11 (−0.69, 2.90) | 0.225 |
| 10 to <20 years | 0.19 | 1.02 (−0.63, 2.67) | 0.226 |
| >20 years | 0.38 | 2.01 (0.18, 3.83) | 0.031 |
| SLEDAI-2K, per 1-point increase | 0 | −0.01 (−0.12, 0.11) | 0.924 |
| Depressive symptom | 0.39 | 2.07 (0.53, 3.62) | 0.009 |
| Experience of ADE within 1 month | 0.42 | 2.18 (0.85, 3.51) | 0.001 |
| Concern for medication number | −0.28 | −1.44 (−2.84, −0.049) | 0.043 |
| Prednisolone dosage, per 1-mg increase | 0 | 0.01 (−0.08, 0.09) | 0.900 |
| Other immunosuppressants | −0.13 | −0.66 (−1.80, 0.48) | 0.258 |
| HCQ | 0.04 | 0.22 (−1.01, 1.45) | 0.723 |
| Prescription for dyslipidaemia | −0.02 | −0.12 (−1.39, 1.14) | 0.850 |
| Prescription for hypertension | −0.05 | −0.27 (−1.40, 0.86) | 0.640 |
| Prescription for diabetes | 0.06 | 0.31 (−1.98, 2.61) | 0.787 |
| Prescription for osteoporosis prevention | 0.20 | 1.07 (−0.27, 2.41) | 0.116 |
| Prescription for PCP prevention | −0.05 | −0.28 (−1.58, 1.01) | 0.669 |
The general linear model was fit with inclusion of all variables listed above. To calculate the corresponding standardized ES (Cohen’s d), the point estimate was divided by the s.d. of the medication adherence scale score.
Bold font indicates significance at P < 0.05 in P-value column. ES: effect size; SLEDAI-2K: SLEDAI 2000; ADE: adverse drug event; PCP: Pneumocystis jirovecii pneumonia.
instead of:
Associations of medication adherence with the Health-related Hope score, trust in the physician, and covariatesa (n = 373)
| . | Corresponding standardized ES . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|---|
| Health-related Hope, per 10-point increase | 0.12 | 0.64 (0.33, 0.95) | <0.001 |
| Trust in one’s physician, per 10-point increase | 0.17 | 0.88 (0.53, 1.24) | <0.001 |
| Basic health literacy, per 1-point increase | −0.06 | −0.33 (−1.18, 0.52) | 0.441 |
| Age, per 10-year increase | −0.02 | −0.12 (−0.6, 0.36) | 0.624 |
| Female vs male subjects | 0.29 | 1.53 (−0.2, 3.26) | 0.083 |
| Marital status | |||
| Married | Reference | ||
| Divorced/widowed | 0 | 0.03 (−2.21, 2.26) | 0.982 |
| Unmarried | 0.22 | 1.15 (−0.16, 2.46) | 0.085 |
| Education | |||
| Junior high school or lower | Reference | ||
| High school/college | 0.03 | 0.16 (−2.51, 2.82) | 0.907 |
| University/graduate school | 0.09 | 0.46 (−2.31, 3.24) | 0.742 |
| Household income | |||
| <1 000 000 yen (very low) | Reference | ||
| 1 000 000–<5 000 000 yen (low-medium) | 0.11 | 0.57 (−1.39, 2.52) | 0.569 |
| 5 000 000–<10 000 000 yen (medium-high) | 0.19 | 0.98 (−1.05, 3) | 0.342 |
| >10 000 000 yen (high) | 0.15 | 0.78 (−1.94, 3.5) | 0.574 |
| Disease duration | |||
| <5 years | Reference | ||
| 5 to <10 years | 0.19 | 1.02 (−0.78, 2.82) | 0.267 |
| 10 to <20 years | 0.18 | 0.95 (−0.7, 2.61) | 0.259 |
| >20 years | 0.37 | 1.93 (0.09, 3.78) | 0.040 |
| SLEDAI-2K, per 1-point increase | 0 | 0 (−0.12, 0.11) | 0.967 |
| Depressive symptom | 0.37 | 1.96 (0.34, 3.59) | 0.018 |
| Experience of ADE within 1 month | 0.43 | 2.28 (0.98, 3.58) | 0.001 |
| Concern for medication number | −0.28 | −1.45 (−2.89, −0.004) | 0.049 |
| Prednisolone dosage, per 1-mg increase | 0 | 0 (−0.07, 0.08) | 0.918 |
| Other immunosuppressants | −0.13 | −0.66 (−1.82, 0.5) | 0.264 |
| HCQ | 0.04 | 0.24 (−0.98, 1.45) | 0.703 |
| Prescription for dyslipidaemia | −0.01 | −0.03 (−1.3, 1.24) | 0.965 |
| Prescription for hypertension | −0.04 | −0.2 (−1.37, 0.97) | 0.733 |
| Prescription for diabetes | 0.03 | 0.16 (−2.12, 2.44) | 0.888 |
| Prescription for osteoporosis prevention | 0.21 | 1.12 (−0.25, 2.49) | 0.109 |
| Prescription for PCP prevention | −0.06 | −0.31 (−1.59, 0.96) | 0.631 |
| . | Corresponding standardized ES . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|---|
| Health-related Hope, per 10-point increase | 0.12 | 0.64 (0.33, 0.95) | <0.001 |
| Trust in one’s physician, per 10-point increase | 0.17 | 0.88 (0.53, 1.24) | <0.001 |
| Basic health literacy, per 1-point increase | −0.06 | −0.33 (−1.18, 0.52) | 0.441 |
| Age, per 10-year increase | −0.02 | −0.12 (−0.6, 0.36) | 0.624 |
| Female vs male subjects | 0.29 | 1.53 (−0.2, 3.26) | 0.083 |
| Marital status | |||
| Married | Reference | ||
| Divorced/widowed | 0 | 0.03 (−2.21, 2.26) | 0.982 |
| Unmarried | 0.22 | 1.15 (−0.16, 2.46) | 0.085 |
| Education | |||
| Junior high school or lower | Reference | ||
| High school/college | 0.03 | 0.16 (−2.51, 2.82) | 0.907 |
| University/graduate school | 0.09 | 0.46 (−2.31, 3.24) | 0.742 |
| Household income | |||
| <1 000 000 yen (very low) | Reference | ||
| 1 000 000–<5 000 000 yen (low-medium) | 0.11 | 0.57 (−1.39, 2.52) | 0.569 |
| 5 000 000–<10 000 000 yen (medium-high) | 0.19 | 0.98 (−1.05, 3) | 0.342 |
| >10 000 000 yen (high) | 0.15 | 0.78 (−1.94, 3.5) | 0.574 |
| Disease duration | |||
| <5 years | Reference | ||
| 5 to <10 years | 0.19 | 1.02 (−0.78, 2.82) | 0.267 |
| 10 to <20 years | 0.18 | 0.95 (−0.7, 2.61) | 0.259 |
| >20 years | 0.37 | 1.93 (0.09, 3.78) | 0.040 |
| SLEDAI-2K, per 1-point increase | 0 | 0 (−0.12, 0.11) | 0.967 |
| Depressive symptom | 0.37 | 1.96 (0.34, 3.59) | 0.018 |
| Experience of ADE within 1 month | 0.43 | 2.28 (0.98, 3.58) | 0.001 |
| Concern for medication number | −0.28 | −1.45 (−2.89, −0.004) | 0.049 |
| Prednisolone dosage, per 1-mg increase | 0 | 0 (−0.07, 0.08) | 0.918 |
| Other immunosuppressants | −0.13 | −0.66 (−1.82, 0.5) | 0.264 |
| HCQ | 0.04 | 0.24 (−0.98, 1.45) | 0.703 |
| Prescription for dyslipidaemia | −0.01 | −0.03 (−1.3, 1.24) | 0.965 |
| Prescription for hypertension | −0.04 | −0.2 (−1.37, 0.97) | 0.733 |
| Prescription for diabetes | 0.03 | 0.16 (−2.12, 2.44) | 0.888 |
| Prescription for osteoporosis prevention | 0.21 | 1.12 (−0.25, 2.49) | 0.109 |
| Prescription for PCP prevention | −0.06 | −0.31 (−1.59, 0.96) | 0.631 |
The general linear model was fit with inclusion of all variables listed above. To calculate the corresponding standardized ES (Cohen’s d), the point estimate was divided by the s.d. of the medication adherence scale score.
Bold font indicates significance at P < 0.05 in P-value column. ES: effect size; SLEDAI-2K: SLEDAI 2000; ADE: adverse drug event; PCP: Pneumocystis jirovecii pneumonia.
Associations of medication adherence with the Health-related Hope score, trust in the physician, and covariatesa (n = 373)
| . | Corresponding standardized ES . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|---|
| Health-related Hope, per 10-point increase | 0.12 | 0.64 (0.33, 0.95) | <0.001 |
| Trust in one’s physician, per 10-point increase | 0.17 | 0.88 (0.53, 1.24) | <0.001 |
| Basic health literacy, per 1-point increase | −0.06 | −0.33 (−1.18, 0.52) | 0.441 |
| Age, per 10-year increase | −0.02 | −0.12 (−0.6, 0.36) | 0.624 |
| Female vs male subjects | 0.29 | 1.53 (−0.2, 3.26) | 0.083 |
| Marital status | |||
| Married | Reference | ||
| Divorced/widowed | 0 | 0.03 (−2.21, 2.26) | 0.982 |
| Unmarried | 0.22 | 1.15 (−0.16, 2.46) | 0.085 |
| Education | |||
| Junior high school or lower | Reference | ||
| High school/college | 0.03 | 0.16 (−2.51, 2.82) | 0.907 |
| University/graduate school | 0.09 | 0.46 (−2.31, 3.24) | 0.742 |
| Household income | |||
| <1 000 000 yen (very low) | Reference | ||
| 1 000 000–<5 000 000 yen (low-medium) | 0.11 | 0.57 (−1.39, 2.52) | 0.569 |
| 5 000 000–<10 000 000 yen (medium-high) | 0.19 | 0.98 (−1.05, 3) | 0.342 |
| >10 000 000 yen (high) | 0.15 | 0.78 (−1.94, 3.5) | 0.574 |
| Disease duration | |||
| <5 years | Reference | ||
| 5 to <10 years | 0.19 | 1.02 (−0.78, 2.82) | 0.267 |
| 10 to <20 years | 0.18 | 0.95 (−0.7, 2.61) | 0.259 |
| >20 years | 0.37 | 1.93 (0.09, 3.78) | 0.040 |
| SLEDAI-2K, per 1-point increase | 0 | 0 (−0.12, 0.11) | 0.967 |
| Depressive symptom | 0.37 | 1.96 (0.34, 3.59) | 0.018 |
| Experience of ADE within 1 month | 0.43 | 2.28 (0.98, 3.58) | 0.001 |
| Concern for medication number | −0.28 | −1.45 (−2.89, −0.004) | 0.049 |
| Prednisolone dosage, per 1-mg increase | 0 | 0 (−0.07, 0.08) | 0.918 |
| Other immunosuppressants | −0.13 | −0.66 (−1.82, 0.5) | 0.264 |
| HCQ | 0.04 | 0.24 (−0.98, 1.45) | 0.703 |
| Prescription for dyslipidaemia | −0.01 | −0.03 (−1.3, 1.24) | 0.965 |
| Prescription for hypertension | −0.04 | −0.2 (−1.37, 0.97) | 0.733 |
| Prescription for diabetes | 0.03 | 0.16 (−2.12, 2.44) | 0.888 |
| Prescription for osteoporosis prevention | 0.21 | 1.12 (−0.25, 2.49) | 0.109 |
| Prescription for PCP prevention | −0.06 | −0.31 (−1.59, 0.96) | 0.631 |
| . | Corresponding standardized ES . | Mean difference, point estimate (95% CI) . | P-value . |
|---|---|---|---|
| Health-related Hope, per 10-point increase | 0.12 | 0.64 (0.33, 0.95) | <0.001 |
| Trust in one’s physician, per 10-point increase | 0.17 | 0.88 (0.53, 1.24) | <0.001 |
| Basic health literacy, per 1-point increase | −0.06 | −0.33 (−1.18, 0.52) | 0.441 |
| Age, per 10-year increase | −0.02 | −0.12 (−0.6, 0.36) | 0.624 |
| Female vs male subjects | 0.29 | 1.53 (−0.2, 3.26) | 0.083 |
| Marital status | |||
| Married | Reference | ||
| Divorced/widowed | 0 | 0.03 (−2.21, 2.26) | 0.982 |
| Unmarried | 0.22 | 1.15 (−0.16, 2.46) | 0.085 |
| Education | |||
| Junior high school or lower | Reference | ||
| High school/college | 0.03 | 0.16 (−2.51, 2.82) | 0.907 |
| University/graduate school | 0.09 | 0.46 (−2.31, 3.24) | 0.742 |
| Household income | |||
| <1 000 000 yen (very low) | Reference | ||
| 1 000 000–<5 000 000 yen (low-medium) | 0.11 | 0.57 (−1.39, 2.52) | 0.569 |
| 5 000 000–<10 000 000 yen (medium-high) | 0.19 | 0.98 (−1.05, 3) | 0.342 |
| >10 000 000 yen (high) | 0.15 | 0.78 (−1.94, 3.5) | 0.574 |
| Disease duration | |||
| <5 years | Reference | ||
| 5 to <10 years | 0.19 | 1.02 (−0.78, 2.82) | 0.267 |
| 10 to <20 years | 0.18 | 0.95 (−0.7, 2.61) | 0.259 |
| >20 years | 0.37 | 1.93 (0.09, 3.78) | 0.040 |
| SLEDAI-2K, per 1-point increase | 0 | 0 (−0.12, 0.11) | 0.967 |
| Depressive symptom | 0.37 | 1.96 (0.34, 3.59) | 0.018 |
| Experience of ADE within 1 month | 0.43 | 2.28 (0.98, 3.58) | 0.001 |
| Concern for medication number | −0.28 | −1.45 (−2.89, −0.004) | 0.049 |
| Prednisolone dosage, per 1-mg increase | 0 | 0 (−0.07, 0.08) | 0.918 |
| Other immunosuppressants | −0.13 | −0.66 (−1.82, 0.5) | 0.264 |
| HCQ | 0.04 | 0.24 (−0.98, 1.45) | 0.703 |
| Prescription for dyslipidaemia | −0.01 | −0.03 (−1.3, 1.24) | 0.965 |
| Prescription for hypertension | −0.04 | −0.2 (−1.37, 0.97) | 0.733 |
| Prescription for diabetes | 0.03 | 0.16 (−2.12, 2.44) | 0.888 |
| Prescription for osteoporosis prevention | 0.21 | 1.12 (−0.25, 2.49) | 0.109 |
| Prescription for PCP prevention | −0.06 | −0.31 (−1.59, 0.96) | 0.631 |
The general linear model was fit with inclusion of all variables listed above. To calculate the corresponding standardized ES (Cohen’s d), the point estimate was divided by the s.d. of the medication adherence scale score.
Bold font indicates significance at P < 0.05 in P-value column. ES: effect size; SLEDAI-2K: SLEDAI 2000; ADE: adverse drug event; PCP: Pneumocystis jirovecii pneumonia.
These corrections have now been made in the article.
Comments